Medical Staff Pulse Newsletter

FDA Strengthens Warning About Clozapine

The U.S. Food and Drug Administration (FDA) is strengthening an existing warning that constipation caused by the schizophrenia medicine clozapine (Clozaril, Fazaclo ODT, Versacloz, generics) can progress to serious bowel complications. This can lead to hospitalization or even death if constipation is not diagnosed and treated quickly.

Clozapine affects how the intestines function in the majority of patients. It produces effects ranging from constipation (trouble having a bowel movement), which is a common occurrence, to serious but uncommon bowel problems including complete blockage of the bowel.

The FDA website has more information.